The Net Margin of Insmed Incorporated (INSM) is
-210.54%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
-210.54%
|
| 2024-12-31 |
-251.24%
|
| 2023-12-31 |
-245.59%
|
| 2022-12-31 |
-196.21%
|
| 2021-12-31 |
-230.61%
|
| 2020-12-31 |
-178.89%
|
| 2019-12-31 |
-186.30%
|
| 2018-12-31 |
-3309.18%
|
| Ticker |
Name |
Value |
|
CDMO
|
Avid Bioservices Inc
|
-100.60%
|
|
CRIS
|
Curis Inc
|
-80.29%
|
|
HRTX
|
Heron Therapeutics Inc
|
-13.04%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
XNCR
|
Xencor, Inc.
|
-73.20%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
PGEN
|
Precigen, Inc.
|
-2588.21%
|
|
BCRX
|
BioCryst Pharmaceuticals, Inc.
|
30.16%
|
|
MYGN
|
Myriad Genetics, Inc.
|
-44.38%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
SRNE
|
Sorrento Therapeutics Inc
|
-912.10%
|
|
VCEL
|
Vericel Corporation
|
5.98%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
MGNX
|
MacroGenics Inc
|
-49.91%
|
|
ORGO
|
Organogenesis Holdings Inc.
|
6.56%
|
|
STRO
|
Sutro Biopharma Inc
|
-186.45%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
LXRX
|
Lexicon Pharmaceuticals, Inc.
|
-101.08%
|
|
MORF
|
Morphic Holding Inc
|
-29192.90%
|
|
ZNTL
|
Zentalis Pharmaceuticals, Inc.
|
-245.96%
|
|
EDIT
|
Editas Medicine, Inc.
|
-395.01%
|
|
MDGL
|
Madrigal Pharmaceuticals, Inc.
|
-30.08%
|
|
PTCT
|
PTC Therapeutics, Inc.
|
39.44%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
ACAD
|
Acadia Pharmaceuticals Inc.
|
36.49%
|
|
AGIO
|
Agios Pharmaceuticals, Inc.
|
-764.01%
|
|
AMRN
|
Amarin Corporation PLC
|
-18.16%
|
|
CLDX
|
Celldex Therapeutics, Inc.
|
-16748.03%
|
|
SRRK
|
Scholar Rock Holding Corporation
|
-405.21%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
CBPO
|
China Biologic Products Holdings Inc
|
29.04%
|
|
ENTA
|
Enanta Pharmaceuticals Inc
|
-125.36%
|
|
MDXG
|
MiMedx Group, Inc.
|
11.60%
|
|
TVTX
|
Travere Therapeutics, Inc.
|
-5.21%
|